title: [Pharmacological and clinical profiles of panitumumab injection (Vectibix®)].
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Matsudaira
authors.forename: Daisuke
authors.initials: D
authors.lastname: Asahi
authors.forename: Ikuo
authors.initials: I
authors.lastname: Yana
authors.forename: Masayuki
authors.initials: M
authors.lastname: Aboshi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015195:Drug Design; D004815:Epidermal Growth Factor; D066246:ErbB Receptors / Q000276:immunology / Q000502:physiology; D006801:Humans; D007262:Infusions, Intravenous; D051379:Mice; D058990:Molecular Targeted Therapy; D009154:Mutation; D009368:Neoplasm Transplantation; D000077544:Panitumumab; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D015398:Signal Transduction / Q000187:drug effects; D018631:ras Proteins / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D004815:Epidermal Growth Factor; D000077544:Panitumumab; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins